NEW RAPID MOOD SCREENER (RMS) SCREENS FOR MANIC SYMPTOMS AND BIPOLAR I DISORDER FEATURES TO ADDRESS UNMET CLINICAL NEED
VANCOUVER, BRITISH COLUMBIA – February 3, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder – is published in Taylor and Francis.com. To review the Article, click here.
Depressive episodes and symptoms of bipolar I disorder are commonly misdiagnosed as major depressive disorder (MDD) in primary care. The novel and pragmatic Rapid Mood Screener (RMS) was developed to screen for manic symptoms and bipolar I disorder features (e.g., age of depression onset) to address this unmet clinical need.
“Timely and accurate diagnoses are precursors of good clinical outcomes in persons with treatment-resistant mood disorders, the high rate of missed bipolar disorder diagnosis is a critical unmet need,” said Dr. Roger McIntyre. “The Rapid Mood Screener provides a systematic approach to screening for bipolar disorder amongst all patients who present with depressive symptoms. It is hoped that greater accuracy in diagnosing bipolar disorder and differentiating bipolar disorder from major depressive disorder is the first step to improving health outcomes for persons affected by mood disorders. Timely screening for bipolar disorder provides the basis for subsequently diagnosing bipolar disorder where applicable and selecting the appropriate treatment.
The 6-item patient-administered RMS differentiates bipolar I disorder from MDD in patients with depressive symptoms, providing real-world guidance to primary care practitioners on whether a more comprehensive assessment for bipolar I disorder is warranted.
Bipolar I disorder is a chronic and debilitating mental illness that is characterized by a mixture of manic, depressive, and subsyndromal symptoms. Although the presence or history of at least one fully syndromal manic episode is required for a diagnosis of bipolar I disorder, depressive symptoms are the more common presentation.
Delayed or missed diagnosis of bipolar disorder is exceedingly common; the delay between the onset of illness and diagnosis of bipolar disorder was reported to be 6–13 years. Unipolar depression was cited as the most common misdiagnosis (60%). An estimated 1 in 4 patients treated for major depressive disorder (MDD) may actually have bipolar disorder, which is a clinical concern given the importance of early intervention and appropriate treatment.
As well as CEO of Champignon Brands, Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. In addition to his recent publication of this article, Dr. McIntyre has published over 670 peer-reviewed scientific articles on bipolar disorders and depression.
Champignon Brands Inc. (http://braxiascientific.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. (“AltMed”). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO
FOR FURTHER INFORMATION PLEASE CONTACT: Champignon Brands Inc. (416) 762-2138
Email: [email protected] Website: www.champignonbrands.com
Media: Victoria Ollers, firstname.lastname@example.org, 416 822-2288
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company’s limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.
Symbols – CSE: BRAX OTC: BRAXF FWB: 496